R. Féty
About
In The Last Decade
R. Féty
15 papers receiving 210 citations
Peers
Comparison fields: 5 of 59
- Oncology 138
- Molecular Biology 47
- Pulmonary and Respiratory Medicine 41
- Cellular and Molecular Neuroscience 33
- Pathology and Forensic Medicine 24
Countries citing papers authored by R. Féty
This map shows the geographic impact of R. Féty's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. Féty with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. Féty more than expected).
Fields of papers citing papers by R. Féty
This network shows the impact of papers produced by R. Féty. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. Féty. The network helps show where R. Féty may publish in the future.
Co-authorship network of co-authors of R. Féty
This figure shows the co-authorship network connecting the top 25 collaborators of R. Féty. A scholar is included among the top collaborators of R. Féty based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R. Féty. R. Féty is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 4 | |
| 2 | Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas. | 96 |
| 3 | 2 | |
| 4 | 3 | |
| 5 | Docetaxel combined with vinorelbine: phase I results and new study designs. | 23 |
| 6 | 12 | |
| 7 | Clinical randomized study of 5FU monitoring versus standard dose in patients with head and neck cancer: preliminary results. | 15 |
| 8 | 2 | |
| 9 | 13 | |
| 10 | 6 | |
| 11 | 14 | |
| 12 | 2 | |
| 13 | 9 | |
| 14 | 6 | |
| 15 | 11 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.